MO-C2N-DIAGNOSTICS
C₂N Diagnostics, LLC, a leader in advanced brain health diagnostics, and Eisai Inc., a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.
C₂N executives say the investment reflects the two companies’ shared desire to scale up and provide broad access to its Precivity™ tests, which are innovative blood tests intended for use in patients with cognitive impairment. These tests aim to help healthcare providers determine Alzheimer’s disease pathology, and aid in medical management and treatment decisions.
The companies agree that Eisai’s investment will catalyze C₂N’s efforts to expand the availability, accessibility and use of high-performance blood biomarker tests for the early diagnosis of Alzheimer’s disease in the U.S.
Dr. Joel Braunstein, C₂N’s CEO, said, “We greatly appreciate the dedication and thoroughness Eisai brought to evaluating the value and quality of our advanced diagnostic solutions in the field of brain health. With this financing, we’re building on our history of attracting the highest-quality investors committed to changing the trajectory of Alzheimer’s disease through early detection and treatment and, ultimately, prevention. We’re proud to have Eisai’s leadership in the field as we’re transforming the management and clinical care standard for patients with Alzheimer’s disease. The availability of blood biomarkers that are closely correlated with gold standard measures, such as positron emission tomography (PET) scans, will improve accessibility for patients to obtain safe and effective drug treatments as more become available.”
“The field of highly accurate blood-based diagnostics is rapidly advancing and expanding,” said Keisuke Naito, Global Alzheimer's Disease Officer, Senior Vice President, Eisai. “Given the expense and capacity limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem’s growth. The availability of more affordable and minimally invasive diagnostic tools helps support broad access for the management of Alzheimer’s disease.”
C2N and Eisai initially announced in 2022 that they were working “to build awareness and develop real-world evidence to support the use of blood-based assays in people living with cognitive impairment who are not currently participating in a clinical trial.”
About C2N Diagnostics, LLC
C₂N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C₂N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C₂N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C₂N assays have been used in over 150 Alzheimer’s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease. C₂N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer’s Association, and other non-profits and consortiums. Over 15,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.
The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation and Alzheimer’s Association. For more information visit www.C2N.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306427979/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avinor Selects Thales to Deploy Norway’s Next-Generation Nationwide Unmanned Traffic Management System9.12.2024 09:00:00 CET | Press release
Thales and Avinor have partnered to implement Norway’s next-generation nationwide Unmanned Traffic Management (UTM) system, enhancing airspace management for both unmanned and manned aircraft while ensuring full compliance with European regulatory standards. Thales' Topsky - UAS, powered by AstraUTM, will provide a scalable, automated platform for real-time traffic management, compliance monitoring, and safe integration of unmanned aircraft, paving the way for efficient air mobility operations across Norway. The new UTM system supports Norway’s vision for unmanned aviation, enabling safe, scalable drone operations and laying the groundwork for future Advanced Air Mobility (AAM) solutions alongside traditional aviation. This strategic partnership with Avinor, the Norwegian air navigation service provider and airport operator, will enable the deployment of Norway’s next-generation nationwide Unmanned Traffic Management system. This collaboration represents a major step forward in Norway’
Avanza Fonder Appoints Northern Trust to Provide Integrated Trading Solutions9.12.2024 09:00:00 CET | Press release
Selected as a Provider of Trading Servicesfor Selected Index Funds Managed by Avanza Fonder Northern Trust (Nasdaq: NTRS) today announced its Integrated Trading Solutions (ITS) outsourced trading desk is supporting Avanza Fonder, a Stockholm-based fund company providing services for private clients. Founded in 2006, Avanza Fonder is a wholly owned subsidiary of Avanza Bank Holding AB (publ). The fund company manages funds in-house and in collaboration with other managers. Northern Trust will provide outsourced trading primarily for Avanza Fonder’s Global, Emerging Market, European and US equity market index funds. Gerard Walsh, global head of Client Solutions Banking & Markets, atNorthern Trust,said: “We are delighted to be working with Avanza Fonder, a leading fund manager in the Nordic region, to support them across the trading spectrum through an integrated middle-and back-office solution. Our customised services will help Avanza Fonder navigate ongoing global market challenges, all
Kapacity.io Acquired by U.S.-based EnergyHub to Accelerate Demand-Side Flexibility in Europe9.12.2024 07:30:00 CET | Press release
Acquisition will help expand electricity retailer partnerships across Europe to drive savings for customers with distributed energy resources Kapacity.io, a European leader in heat pump optimization and flexibility, has been acquired by EnergyHub, North America's largest provider of residential flexibility solutions. Backed by EnergyHub’s resources and experience, Kapacity.io will continue to focus on expanding partnerships with electricity retailers and heat pump manufacturers to unlock the benefits of residential flexibility for consumers. EnergyHub’s distributed energy resource management system (DERMS) manages more than 1.5 million distributed energy resources (DERs) across over 100 utility programs in North America. Kapacity.io helps retailers optimize the energy consumption of heat pumps on dynamic tariffs and other flexibility offerings and provides congestion management and grid balancing services to distribution system operators (DSOs) and transmission system operators (TSOs),
FPT and RWE Sign 5-Year Master Service Agreement to Drive Innovation and Sustainability9.12.2024 03:30:00 CET | Press release
FPT has signed a five-year Master Service Agreement (MSA) with RWE, further strengthening the longstanding partnership between the two companies. The agreement aims to advance technological innovation, operational excellence, and sustainable growth, supporting RWE’s ambitious initiatives in IT/OT convergence, renewable energy, and data-driven solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241208877842/en/ The signing ceremony took place in Essen, Germany, with the participation of Ms. Katja van Doren, Member of the Executive Board of RWE AG (L), Mdm. Chu Thi Thanh Ha, FPT Software Chairwoman (R), and senior leaders of both companies. (Photo: Business Wire) The signing ceremony in Essen, Germany, marks the beginning of an enhanced collaboration where FPT will provide a robust offshore utilization strategy through its Offshore Delivery Center. This will enable cost-effective, scalable solutions tailored to RWE’s evo
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update8.12.2024 18:52:00 CET | Press release
- Data from long-term follow-up of patients in clinical trials further demonstrate durability of the transformative benefits of CASGEVY™ - - Safety profile consistent with busulfan conditioning andautologous hematopoietic stem cell transplant -- Vertex provides update on progress in bringing CASGEVY to patients - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy. The results, presented at the American Society of Hematology (ASH) Annual Meeting and Exposition, continue to demonstrate the transformative, durable clinical benefits of CASGEVY. The longest follow up for both SCD and TDT patients now extends more than 5 years, with a median of 33.2 months and 38.1 months, respectively. “These comprehensive data provide additio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom